Document Detail


Von Willebrand's disease and angiodysplasia treated with thalidomide.
MedLine Citation:
PMID:  16643215     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A 54-year-old man with type IIB VWD and severe angiodysplasia had such a large blood loss from the bowel that it was difficult to keep up with transfusion requirements. Treatment with factor eight concentrate barely slowed the loss. D.D.A.V.P., Octreotide, and recombinant activated Factor VII, tried separately, were ineffective. The use of Thalidomide at a dose of 150 mg daily has rendered him free from blood loss for the last six months and we suggest would be worth a trial in similar cases.
Authors:
H M Hirri; P J Green; J Lindsay
Related Documents :
15170275 - Evaluation of hemorrhage depressors on blood loss during orthognathic surgery: a retros...
10534425 - Hypervolemic hemodilution: an alternative to acute normovolemic hemodilution? a mathema...
2413195 - Major childhood tumor resection using normovolemic hemodilution anesthesia and hetastarch.
16089085 - Effects of recombinant hematopoietins on blood-loss anemia in mice.
18799835 - Unconstrained parameter estimation for assessment of dynamic cerebral autoregulation.
17249325 - Hemorheological changes in microcirculation: their mechanism and measurement technique.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  12     ISSN:  1351-8216     ISO Abbreviation:  Haemophilia     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-04-28     Completed Date:  2006-09-29     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  England    
Other Details:
Languages:  eng     Pagination:  285-6     Citation Subset:  IM    
Affiliation:
Portsmouth Hospitals NHS Trust, Portsmouth, UK. Hussain.Hirri@porthosp.nhs.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiodysplasia / complications,  drug therapy*
Angiogenesis Inhibitors / therapeutic use*
Humans
Male
Middle Aged
Thalidomide / therapeutic use*
Treatment Outcome
von Willebrand Diseases / complications,  drug therapy*
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune...
Next Document:  Patient injuries in response to anaesthetic procedures: cases evaluated by the Danish Patient Insura...